



Gary Schwartz, MD
 Co-Chair for Experimental Therapeutics and Rare Tumor Committee
 Columbia University
 177 Fort Washington Avenue, Suite 6GN-435
 New York, NY 10032
 Phone: 212-305-2055
 Email: Schwartzg@columbia.edu

Pamela N. Munster, MD
 Co-Chair for Experimental Therapeutics and Rare Tumor Committee
 University of California San Francisco
 1600 Divisadero, Rm A722 Box 1770
 San Francisco, CA 97143
 Phone: 415-502-3598
 Email: Pmunster@medicine.ucsf.edu

Date: April 4, 2018

To: Experimental Therapeutics and Rare Tumor Committee

From: Gary Schwartz, MD
 Pamela Munster, MD

Re: **Experimental Therapeutics and Rare Tumor Committee Meeting**

Date: **Thursday, May 10, 2018**

Time: **11:30am – 3:00pm Central**

Location: Loews Chicago O’Hare - Rosemont, IL 60018
 Room Cassatt C/D

Call-In Information: (800) 501-8979 / Access Code: 8087368

AGENDA

1. Status update on activated current trials: *Munster*

a.	A091202 (suspended)	A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unresectable Myxoid Liposarcoma	M. Pishvaian
b.	A091302	Randomized Phase II study of Sorafenib With or Without Everolimus in Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer	E. Sherman
c.	A091304	A Phase I/Randomized Phase II Study of MLN-0128 vs. Pazopanib in Patients with Advanced/Unresectable and/or Metastatic Sarcoma	W. Tap
d.	A091305	A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, in Combination with Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer	R. Smallridge

e.	A091401	Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma	S. D'Angelo
f.	A091404	A Phase II Study of Enzalutamide for Patients with Androgen Receptor Positive Salivary Cancers	A. Ho
g.	A091605	Randomized Phase II Study of Stereotactic Body Radiotherapy + anti-PD1 antibody (pembrolizumab) in advanced Merkel Cell Carcinoma	J. Luke S. Chmura

2. Status update on current trials in development: *Schwartz*

a.	A091607	A randomized phase II study of CDX-1401 in combination with Atezolizumab in patients with locally advanced or metastatic NY-ESO-1 positive synovial sarcoma	S. Robinson
b.	A091802	Phase II single arm trial of Avelumab plus Cetuximab in advanced cutaneous Squamous Cell Carcinoma (SCC)	D. Zandberg

3. Status of Concepts: *Munster*

a.	Phase II Randomized Study of Atezolizumab (PDL-1 inhibitor) alone or in combination with Obinutuzumab (anti-CD20) for Recurrent-Metastatic Head and Neck Squamous cell carcinoma , following progression of disease on previous lines of therapy (A091704)		M. Matsangou
b.	Reversing Resistance to Pazopanib with Histone Deacetylase Inhibition: A Phase 1b Dose Escalation/Expansion Study (A091801)		P. Munster
c.	An Open-Label Phase II Study with Safety Lead-In of TAK228 in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Ewing sarcoma, and Osteosarcoma		E. Slotkin

4. New Concepts: *Schwartz*

a.	Synthetic Lethality with VX970+ Doxil: A Phase 1 study		M. Dhawan
b.	Adjuvant nivolumab for <u>PeRItoneaL</u> mesothelioma (APRIL)		A. Mansfield